GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas' LNP technology. Under the terms of the agreement, GC Biopharma will obtain the option to license Acuitas' LNP technology for up to four undisclosed targets, on a non-exclusive basis, for vaccine or therapeutic development. GC Biopharma has selected mRNA as the new development platform and has been conducting related research since late 2017.